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Metabolic syndrome signiﬁcantly increases the risk for cardiovascular disease and chronic kidney disease. The increased risk
for cardiovascular diseases can partly be caused by a prothrombotic state that exists because of abdominal obesity. Multiple
observational studies have consistently shown that increased body mass index as well as insulin resistance and increased
fasting insulin levels is associated with chronic kidney disease, even after adjustment for related disorders. Metabolic syndrome
appears to be a risk factor for chronic kidney disease, likely due to the combination of dysglycemia and high blood pressure.
Metabolicsyndromeisassociatedwithmarkedlyreduced renalclinicalbeneﬁtandincreasedprogressiontohemodialysisfollowing
endovascular intervention for atherosclerotic renal artery stenosis. Metabolic syndrome is associated with inferior early outcomes
for dialysis access procedures.
1.Introduction
Metabolic syndrome is evolving into a pandemic, con-
tributing to approximately 6-7% for all-cause mortality, 12–
17% for cardiovascular disease, and 30–52% for diabetes
in the population [1]. In populations free of cardiovascular
disease at baseline, cardiovascular morbidity and mortality
increases 1.5- to 3-fold in the presence of the metabolic
syndrome [2, 3]. Two deﬁnitions of metabolic syndrome
predominate the literature, the National Cholesterol Educa-
tion Program (NCEP) and the World Health Organization
(WHO). Metabolic syndrome is deﬁned as the presence of
3 or more of the following: (1) waist circumference ≥88cm
in women and ≥102cm in men, (2) fasting triglycerides
≥150mg/dL or drug treatment for elevated triglycerides, (3)
HDL-cholesterol < 50mg/dL in women and < 40mg/dL
in men or drug treatment for reduced HDL-cholesterol,
(4) BP ≥ 130/85mmHg or use of BP-lowering medication,
and (5) fasting glucose ≥100mg/dL or use of glucose-
lowering medication, according to the American Heart
Association/National Heart, Lung, and Blood Institute
(AHA/NHLBI), updated National Cholesterol Education
Program (NCEP), and Adult Treatment Panel III (ATPIII)
criteria [4]. If waist circumference is not available, a body
mass index (BMI) > 30kg/m2 can be used as a determinant
for abdominal obesity [5]. Metabolic syndrome appears to
be a risk factor for chronic kidney disease, likely due to
the combination of dysglycemia, a prothrombotic state and
high blood pressure. This paper examines the relationship
between metabolic syndrome and the development of and
interventions for renal artery and renal parenchymal disease.
2.Coagulation
The increased risk for cardiovascular diseases could partly
be caused by a prothrombotic state that exists because
of abdominal obesity. Adipose tissue induces thrombocyte
activation by the dysregulated production of adipose tissue-
derived hormones, often called adipokines, which have
been shown to interfere with platelet function. Enhanced
platelet aggregation and activation markers are associated
with low adiponectin concentrations [6]. Increased adipose
tissuemass inducesinsulinresistanceandsystemic low-grade
inﬂammation, also aﬀecting platelet function. It has been
demonstrated thatadipose tissue directly impairs ﬁbrinolysis2 Cardiology Research and Practice
by the production of plasminogen activator inhibitor-1
and possibly thrombin-activatable ﬁbrinolysis inhibitor [7].
Adipose tissue may contribute to enhanced coagulation by
direct tissue factor production, but hypercoagulability is
likely to be primarily caused by altered hepatic synthesis of
the coagulation factors ﬁbrinogen, factor VII, factor VIII,
and tissue factor, by releasing free fatty acids and proin-
ﬂammatory cytokines (tumor necrosis factor-α,i n t e r l e u k i n -
1β, and interleukin-6) into the portal circulation and by
inducing hepatic insulin resistan c e .A d i p o s et i s s u ed y s f u n c -
tion could thus play a causal role in the prothrombotic
state observed in obesity, by directly and indirectly aﬀecting
hemostasis, coagulation, and ﬁbrinolysis [8]. Platelets in
type 2 diabetic individuals adhere to vascular endothelium
and aggregate more readily than those in healthy people.
Loss of sensitivity to the normal homeostatic restraints
exercised by prostacyclin (PGI2) and nitric oxide (NO)
generated by the vascular endothelium presents as the major
defect in platelet function. Insulin is a natural antagonist
of platelet hyperactivity. It sensitizes the platelet to PGI2
and enhances endothelial generation of PGI2and NO. Thus,
the defects in insulin action in diabetes create a milieu
of disordered platelet activity conducive to macrovascular
and microvascular events. Patients with type 2 diabetes and
abdominal fat patterning displayed higher plasma activities
of clotting factors VII and VIII as well as increased plasma
levelsof ﬁbrinogen and von Willebrand factor antigen, when
compared with not only healthy normal weight controls,
but also with diabetic patients at normal body weight. An
altered coagulation state has implications for any surgical or
endovascular intervention.
3.Obesity andKidneyDisease
Obesity and the metabolic syndrome signiﬁcantly increase
the risk for cardiovascular disease and chronic kidney
disease. Multiple abnormalities that can lead to kidney
injury have been identiﬁed in overweight and obese peo-
ple, including insulin resistance, compensatory hyperinsu-
linemia, inappropriate activation of the renin-angiotensin-
aldosterone system, increased oxidative stress, endoplasmic
reticulum stress, coagulability, and impaired ﬁbrinolysis.
The combined eﬀects of these conditions induce, in the
kidneys,impaired pressure natriuresis, glomerularhyperten-
sion, endothelial dysfunction, and vasoconstriction, as well
as matrix proliferation and expansion. Among the conse-
quencesare microalbuminuria, now known to be a surrogate
of diﬀuse endothelial dysfunction as well as a predictor
of cardiovascular disease, and chronic kidney disease [9].
Multiple observational studies have consistently shown that
increased body mass index as well as insulin resistance and
increased fasting insulin levels is associated with chronic
kidney disease, even after adjustment for related disorders
[10]. Obesity may promote intracellular lipid accumulation
in the kidney. Prevalence of a body mass index of at least
35kg/m2 among incident dialysis patients has increased by
64% over the past decade, and if these trends continue
20% of all patients will initiate dialysis with this degree of
obesity. Weight loss improves glomerular hemodynamics in
morbidly obese adultsand may retard progression ofchronic
kidney disease. In contrast, once a patient reaches end-
stage renal disease, the degree of adiposity correlates with
survival, and weight loss may not necessarily be beneﬁcial
[11]. Metabolic syndrome appears to be a risk factor for
chronic kidney disease, likely due to the combination of
dysglycemia and high blood pressure. Metabolic syndrome is
associated with markedly reduced renal clinical beneﬁt and
increased progression to hemodialysis following endovascu-
lar intervention for atherosclerotic renal artery stenosis.
4.CardiovascularRiskandPeripheral
VascularProcedures
Patients with peripheral arterial disease and metabolic
syndrome have an increased risk for the development of
cardiovascular (CV) events, when compared to patients
without metabolic syndrome (27% versus 18% and 27%
versus 19%, P<. 001, resp.). In peripheral arterial disease,
metabolic syndrome was independently associated with an
increased risk of long-term CV events (HR = 1.6; 95% CI
1.2–2.1and HR = 1.4;95%CI1.1–1.8)butnotCVmortality
[12]. A survey of patients with intermittent claudication
and ankle/brachial index (ABI) < 0.90 showed that 52.6%
meet the revised version of the Adults Treatment Panel III
(rATP III) criteria for metabolic syndrome [13]. In women,
metabolic syndrome is associated with an increased risk
of future symptomatic peripheral arterial disease. This risk
appears to be mediated largely by the eﬀectsof inﬂammation
(increased levels of high-sensitivity C-reactive protein) and
endothelial activation (increased levels of soluble intercellu-
lar adhesion molecule-1). There is currently no data on the
impact of metabolic syndrome on outcomes in peripheral
interventions. After open aneurysm repair, obesity of any
class is independently predictive of wound complications.
Class III obesity was also an independent predictor of
renal complications and cardiac complications. After EVAR
(endovascular aortic/aneurysm repair), obesity (any class)
was predictive of wound complications, but not predictive
of other complications or death. For the two types of
operation, there were fewer complications and deaths after
EVAR compared with open repair across all BMI categories,
but outcomes were most disparate among the obese [14].
Obesity is associated with extended operation time during
EVAR. After controlling for age, gender, and operation type,
mortality risk remained lowest in obese class I patients (odds
ratio (OR) 0.63, P = .023), while morbidity risk was highest
inobeseclassIIIpatients(OR1.70,P = .0003),duetowound
infection, thromboembolism, and renal complications [15].
Surgical site infections occur frequentlyafter lower extremity
bypass regardless of bypass origin and are associated with
early graft failure and sepsis. Obesity predicts postoperative
surgical site infections. Mortality risk was greatest in the
underweight, followed by morbidly obese and normal-
weight patients, while overweight and mild to moderate
obesity were associated with the lowest mortality.Cardiology Research and Practice 3
5.InterventionsandRenal
FibromuscularDysplasia
Hypertension is one of the criteria for metabolic syndrome
and one cause of treatable hypertension in women is
ﬁbromuscular dysplasia (FMD) [16]. Percutaneous endovas-
cular intervention for clinically symptomatic ﬁbromuscu-
lar dysplasia in the renal arteries is technically successful
and safe. There are excellent assisted patency and low
restenosis rates with immediate clinical beneﬁt for most
patients and continued long-term results up to 5years
[17]. Using proportional hazard analysis, the predictors of
long-term clinical beneﬁt were duration of hypertension
<8years, creatinine <1.5mg/dL, ipsilateral kidney size, func-
tional status of the contralateral kidney, a fasting blood
sugar <110mg/dL∗, triglycerides <150mg/dL∗,a n dH D L>
50mg/dL∗ (∗components of metabolic syndrome) [17].
Neitherage <50years noradministration ofstatins appeared
to be signiﬁcant. The diagnosis of metabolic syndrome did
not aﬀect outcomes.It appears, however, that the presence of
existing renal pathology and markers of metabolic syndrome
is associated with recurrence of hypertensive symptoms [17].
6.InterventionsandRenal
AtheroscleroticDisease
Endovascular therapy for symptomatic atherosclerotic renal
artery stenosis is common and eﬀective in the well-
selected patient [18, 19]. The proportion of patients with
symptomatic renal artery disease who will have metabolic
syndrome is similar to that described for symptomatic
peripheral vascular disease [20]. These patients will more
often be female, but there is no signiﬁcant diﬀerence in
presenting symptoms. Despite the presence of obesity and
the risks associated with metabolic syndrome, perioperative
mortality and morbidity are equivalent to those without
metabolicsyndrome. Patientswithmetabolicsyndrome have
equivalent survival and cumulative patency. However, the
metabolic syndrome group has a lower 5-year freedom from
restenosis and lower5-yearretained clinicalbeneﬁt(freedom
from recurrent hypertension or worsening renal insuﬃ-
ciency) (Figure 1). However, a higher number of patients
progress to hemodialysis (3% versus 13%, no metabolic
syndromeversusmetabolicsyndrome;P<. 01).Individually,
the components of metabolic syndrome do not inﬂuence
outcomes [20].
7. Dialysis Access
The average BMI of incident dialysis patients in USA has
risen by 13% since 1995, mirroring the expanding obesity
epidemic in USA. This increase in patient weight has
resulted in an increased number of dialysis patients who are
obese (BMI > 30). The impact of BMI on dialysis access
outcomes has been diﬃcult to elucidate, with some studies
showing inferior outcomes for dialysis access procedures
among obese patients, while others do not detect a BMI-
associated outcome eﬀect. When determining the route of
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Figure 1: Kaplan-Meier analysis of freedom from renal-related
morbidity (persistent increase in creatinine >20% of baseline,
progression to hemodialysis, death from renal-related causes) for
the patients with and without MetS. Values are mean.
dialysis access in the obese, proper consideration must be
given to peritoneal dialysis (PD). While the placement of PD
cathetersinobeseindividualsmaybetechnicallychallenging,
there is no decrease in catheter use or catheter survival
in obese patients compared to the nonobese. Obese PD
patients do have higher catheter-exit site infection rates
and a tendency toward poor wound healing. Placement of
autologous ﬁstulae and prosthetic grafts in the obese follows
the same guidelines as in the nonobese. However, in the
case of autologous ﬁstulae, superﬁcialization (i.e., removing
subcutaneous fat to decrease the depth of the vein and allow
cannulization) is more common in these patients and will
delay primary access. There is no data on the impact of
metabolic syndrome on the functionality and longevity of
dialysis access sites.
Metabolic syndrome inﬂuences the development of
chronic renal insuﬃciency and does inﬂuence the outcomes
of percutaneous renal intervention in patients with symp-
tomatic atherosclerotic renal and FMD renal artery disease.
In addition, the presence of obesity, as well as metabolic
syndrome, alters the paradigms for obtaining dialysis access
for those with end-stage renal disease and complicates the
ability to achieve successful and durable access.
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